Lifelong commitment to patients, their families and defeating disease through innovation. Driven by facts & hard data. Inspired by speaking out & compassion
I encourage you to read the following reports.
1. Reuters, November 17, 2026 — How Kennedy let measles run wild in America:
reuters.com/investigations/h…
2. Reuters, August 28, 2025 — US CDC under Kennedy has seen mass layoffs, vaccine policy changes:
reuters.com/legal/litigation…
3. Reuters, October 14, 2025 — CDC set to lose quarter of staff with latest layoffs, union says:
reuters.com/legal/litigation…
4. My earlier LinkedIn warning — Trust Breaks, Consequences Mount: Vaccine Hesitancy and System Failure:
I warned that measles was the canary in the coal mine. The scientific evidence had not changed, but the guidance reaching American families had.
linkedin.com/posts/jeremymle…
5. The scientific origins of the MMR-autism misinformation — The BMJ, January 2011
bmj.com/content/342/bmj.c745…
The evidence is before us. I hope those responsible for America's public health will act.
ROBERT F. KENNEDY JR. IS PRESIDING OVER A PUBLIC HEALTH DISASTER. AMERICA MUST ACT.
Today's Reuters investigation into America's measles resurgence indicts Health Secretary Robert F. Kennedy Jr.
More than 7,700 Americans have contracted measles since 2025. Thirteen have died. Childhood vaccination rates are falling. After 26 years, America has lost its measles-elimination status.
This is a national disgrace.
I have warned of the consequences when ideology replaces science, experts are driven out, and trust in vaccines is undermined. In May, I described measles as the canary in the coal mine. In October, I warned that dismantling the CDC could bring back diseases we had learned to control.
We are now witnessing what I feared.
Kennedy has spent years promoting doubts about vaccines, including claims rooted in the discredited suggestion that MMR vaccination causes autism. That claim originated in Andrew Wakefield's 1998 paper, retracted by The Lancet in 2010 and exposed as fraudulent.
Yet Kennedy challenges established vaccine science while occupying America's highest public health office.
Under his leadership, the CDC has suffered mass staff reductions, the loss of experienced scientific leaders and the removal of independent vaccine advisers. Public health programs have been weakened while preventable diseases spread.
This is not reform. It is the destruction of capabilities that took generations to build.
In Biotech in the Balance, I argued that medicine and biotechnology depend on scientific integrity, independent institutions and public trust. Kennedy's leadership violates those principles. Children should not suffer potentially fatal diseases because of a political appointee's personal convictions.
And measles may be only the beginning.
Tomorrow, November 18, the Senate health committee is scheduled to vote on Heidi Overton's nomination to lead the FDA. Whoever becomes Commissioner will report to Kennedy. How can that individual defend scientific independence when the Secretary repeatedly challenges established medical science?
I cannot believe President Trump intended this outcome. Nor can I imagine any responsible American, Republican or Democrat, would want it.
But the evidence is impossible to ignore, and his administration has the authority and responsibility to act. Kennedy should no longer serve as Secretary of Health and Human Services. The administration must recognize the damage and restore competent scientific leadership.
I call on physicians, scientists, patient advocates, biotechnology leaders and elected representatives of both parties to speak out and demand action.
Silence in the face of this evidence is indefensible.
We have a responsibility to protect children, prevent unnecessary deaths and defend the scientific institutions on which every American depends.
I ask everyone who shares these concerns to add their voice. We must act now, before more lives are lost.
#News#Biotech#Healthcare#USA#RFK#measles
Having waded through 163 pages of the draft COINS rule published by Treasury, my team and I can now respond with a simple graphic.
It will blind US companies and undermine our biopharma capabilities and national security, exactly opposite to what the policy is aiming to achieve. It does nothing to actually block a Chinese biotech from commercializing a drug in the US, with a European partner, European investors, or on its own. We value medicines highly and will now be paying others for them. Why would we do this to ourselves? We shouldn’t.
But you can’t submit a comic to Treasury so we wrote out a detailed comment that both lays out how the draft rule would backfire on American biotech and what revisions would allow Treasury to better achieve their stated national security objectives.
Have a look. Biotech investors and executives are welcome to sign onto our comment but the main purpose of publishing it now is to drive discussion that helps everyone sharpen their thinking and informs their own comment to Treasury, due Dec 7th. Anyone is welcome to crib from this. No need to ask.
We wrote it after considerable input from legal experts and peers. Since coins draft rule is itself unclear on many points, reasonable people can disagree as to its intent and meaning, so some of our comments address broader points meant to encompass a range of possibilities.
If you read what Treasury wrote, you might get the sense that they know this will backfire on America and are looking for support to revise their language to avert harm. So give this thought and submit your own analysis. We provide links in the article to the submission page.
And thanks to all who have already signed on.
@NPLB_orgracap.com/rapport/comment-fr…
The question for American legislators is whether they will make investment in domestic discovery attractive enough to sustain it. Calling biotechnology a strategic industry means little unless policy helps finance the capabilities on which that industry depends.
Venture capital and pharmaceutical companies also bear responsibility. They cannot keep harvesting discoveries without financing the work that produces them. By the time that failure becomes visible in their pipelines, the scientific teams we need may have dispersed.
For reference, the English report and Chinese government announcement:
theedgemalaysia.com/node/822…mofcom.gov.cn/zcfb/dwmygl/ar…
Congress and state legislators should look closely at what China announced today. It shows how a country protects the future of an industry while earning money from its present.
Beijing proposes to restrict foreign ownership of selected biopharma technologies while preserving routes to license the medicines they produce. International partners can help pay for development. Chinese companies keep the platforms, build knowledge and use licensing income to finance further discovery.
Last month, ten Chinese authorities set a goal: at least 25% of the world’s first-in-class drugs should originate in China by 2030. Today’s proposal helps explain how they intend to get there.
America needs to understand what it is watching.
Too many venture investors and pharmaceutical companies will finance a drug after substantial uncertainty has been removed, yet decline to support the discovery capabilities that produced it. They are harvesting decades of scientific investment without adequately replenishing it.
Investors have an obligation to earn returns. Pharmaceutical companies must choose where to commit capital. Some discovery platforms have failed, and calling a company a platform does not make it valuable.
But those arguments do not resolve the national problem. If investing in American discovery is less attractive than buying its output elsewhere, capital will follow. Legislators cannot declare biotechnology a strategic industry and then ignore the incentives determining whether its foundations survive.
Congress should make sustained investment in domestic discovery more attractive. Tax incentives, matching investment and public-private financing should reward pharmaceutical companies and investors that develop and validate platforms here. Support should depend on scientific evidence and continued investment in American research.
Over forty years, in biotech, academic centers and the NIH we have built extraordinary technologies for discovering medicines. Their value resides in people, accumulated knowledge and the ability to keep testing new ideas. When companies close and teams disperse, that capacity is lost. It cannot simply be purchased back when we need it.
I believe we risk a serious discovery cliff in three to five years. The pipeline may conceal the damage for a time. Eventually, the missing investment will mean fewer new candidates and greater dependence on discoveries made elsewhere.
Accelerating the FDA is necessary. Repairing the damage from last year’s research cuts and disruption is necessary. We also need companies capable of discovering what the FDA will review next.
China arranges for international capital to support discovery capabilities it intends to retain. American legislators must give our industry compelling reasons to invest in its own future. Waiting until the pipeline runs thin will be years too late.
#china#usa#biotech#pharma
A vaccine against cancer. And at the same moment, America is retreating from vaccination. So I have a question for those encouraging Americans to distrust vaccines. If you developed melanoma tomorrow and an mRNA vaccine could reduce the risk of your cancer returning, would you refuse it? If not, why encourage parents to fear vaccines that protect their children?
Khattak A, et al. Journal of Clinical Oncology. 2026.
lnkd.in/gJPxwunf
אני מכיר את מורן שנים רבות, וגאה לראות את הדרך שעשתה ואת המנהיגות שהפגינה לאורך השנים.
בפריימריז הקרובים של הדמוקרטים, אני תומך בה בכל ליבי.
בתקופה שבה הדמוקרטיה, השוויון והלכידות הלאומית דורשים מנהיגות אמיצה, מורן זר קצנשטיין כבר הוכיחה היכן היא עומדת.
שירתה בצה״ל. עבדה בשב״כ. מייסדת תנועה שהניעה נשים בכל רחבי ישראל לפעולה. קול אמיץ ובלתי מתפשר למען הדמוקרטיה, השוויון והחברה הישראלית.
ישראל זקוקה ליותר מנהיגות כמו מורן זר קצנשטיין.
להתפקדות:
Moranzer.co.il
The end of the war must be fair, and I am grateful to everyone who stands with Ukraine and our people today for the sake of peace in Ukraine, which is defending the vital security interests of our European nations.
Ukraine values and fully supports the statement by President Macron, Prime Minister Meloni, Chancellor Merz, Prime Minister Tusk, Prime Minister Starmer, President Ursula von der Leyen, and President Stubb on peace for Ukraine.
president.gov.ua/en/news/spi…
The new director of NIH (hired by HHS Secretary Kennedy) said in his role as NIH head on Bannon's podcast that mRNA is "not yet ready for prime time for vaccines" in response to Bannon's comment that FDA-approved mRNA vaccines are an "experimental gene therapy." See clip below:
Merkel cell carcinoma log, day #361 @Cigna has been giving my oncology team at @DanaFarber fits, refusing to cover my fourth Merkel cell carcinoma scan, marking the one-year anniversary of treatment. The scan is absolutely essential, as I've been unable - so far - to get a ctDNA test set up with the scanty tumor tissue available from my original biopsy. (I asked if I needed another biopsy in the beginning, but, hey, didn't happen.) So there's only one radar on recurrence now. Which is the big, big thing for @cancer patients responding (partial remission) to frontline treatment. Evidently, the fourth scan doesn't fit their guidelines, but it's SOP in Merkel cell, when you'd like to take another shot at it if/when frontline fails. So why don't you buy a clue, Cigna, and do what's right here. For all the millions of Americans with cancer who deal with private insurance.
Re MFN/Medicaid, hearing that this particular proposal will face strong opposition from House Republicans (government price controls represent the importation of socialized medicine/drug rationing). But having ex US countries free ride is also not going to fly so the industry must bring to the White House concrete alternative ideas & solutions to address the free riding issue $XBI$BBC
As people chew on MFN this am, it’s worth reminder about other significant US vs. EU healthcare cost differences.
Every system different. You cannot simply import foreign prices.
If we want to really lower prices for Americans, get rid of OOP costs!
Big Pharma has no problem committing billions to moving part of its manufacturing to the US to appease Trump, but they'll fight MFN pricing tooth and nail. I don't see Trump making it stick. But the new bomb throwing destabilizes the industry even more. Heckuva sorry excuse for "reform."
A trawl of job views and application data suggests jobseekers are looking abroad as the Trump administration’s cuts to science take hold.
go.nature.com/4juukPO